

**Date and Time:** 20<sup>th</sup> February 2013 10:00-16:00

**Minutes:** Confirmed

**Multiple Sclerosis GDG Meeting 5**

**Place:** *Linacre Room, Royal College of Physicians, 11 St Andrews Place, London, NW1 4LE*

**Present:** GDG

|                      |     |
|----------------------|-----|
| 1. Jeremy Chataway   | JC  |
| 2. Peter Brex        | PB  |
| 3. Wendy Hendrie     | WH  |
| 4. Susan Hourihan    | SH  |
| 5. Pamela Bostock    | PAB |
| 6. Noreen Barker     | NB  |
| 7. Richard Warner    | RW  |
| 8. Aleks de Gromoboy | ADG |
| 9. Ann Hodgson       | AH  |
| 10. Emma Rowe        | ER  |
| 11. David Kernick    | DK  |

NCGC Technical team

|                                       |     |
|---------------------------------------|-----|
| 12. Norma O'Flynn                     | NOF |
| 13. Mark Perry                        | MP  |
| 14. Amy Kelsey                        | AK  |
| 15. Lina Gulhane – present for note 6 | LG  |
| 16. Krishna Chinthapalli              | KC  |
| 17. Katharina Dworzynski              | KD  |
| 18. Elisabetta Fenu                   | BF  |

Apologies

|                        |    |
|------------------------|----|
| 19. Clifford Middleton | CM |
| 20. Paul Cooper        | PC |
| 21. Sharon Swain       | SS |

## Notes

1. The meeting was chaired by Norma O' Flynn. The Chair welcomed the group to the Multiple Sclerosis Guideline Development Group (GDG) meeting 5. Apologies were received from Paul Cooper, Sharon Swain and Clifford Middleton. The Chair introduced Betta Fenu, NCGC Health Economics Lead, who has taken over from Lola Adedokun. The Chair also introduced Katharina Dworzynski, NCGC Senior Research Fellow, who attended the GDG on behalf of Sharon Swain.
  
2. The Chair asked the GDG to declare any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests  
  
RW declared the following non-personal pecuniary interest: he was part of an advisory board on relapse management for Novartis.  
  
All other GDG members had no change in their previous declarations.
  
3. The Chair introduced Mark Perry, NCGC Research Fellow, who gave the GDG an update on the rehabilitation settings review. The Chair thanked MP for his presentation.
  
4. MP gave a presentation of the clinical evidence of pharmacological management of acute relapse with steroids for adults with MS. BF presented the economic evidence. The GDG discussed the evidence presented and drafted recommendations. The Chair thanked MP and BF for their presentations.
  
5. MP gave a presentation of the clinical evidence regarding advice about modifiable risk factors such as immunisations and pregnancy for adults with MS. The GDG discussed the evidence presented and drafted recommendations. The Chair thanked MP for his presentation.
  
6. MP then led discussion with the GDG on the research protocols for 2 clinical questions. The following research protocols were discussed by the group:
  - For adults with MS, what is the clinical evidence and cost effectiveness of the pharmacological treatment of ataxia and tremor?
  - For adults with MS what is the clinical evidence and cost effectiveness of pharmacological treatment of fatigue?
  
7. The Chair requested that if GDG members are aware of papers that could have been included in the reviews they should inform the technical team as soon as possible in order for the papers to be included before the GDG meeting.
  
8. The Chair closed the meeting and thanked everyone for attending.

## Date, time and venue of the next meeting

9. 4<sup>th</sup> April 2013, 10:00-16:00, Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London, W1W 5QZ